Wolwo Pharma(SZ:300357)2024-06-16 08:40Management Changes - Mr. He Jianming has been appointed as the new General Manager, with a term until the end of the current board's tenure [2] - Mr. Hu Gengxi will continue as Chairman and will focus on sales performance post his transition from General Manager [4] Company Strategy and Product Development - The company will maintain its current strategic direction and product layout, focusing on allergen products while advancing research in stem cells and natural medicines [3] - The first drug molecule for drug-resistant tuberculosis is in preclinical research [4] Financial Performance - In Q1 2024, the company achieved revenue of ¥216,249,528.11, representing an 18.08% increase year-on-year [4] - The net profit attributable to shareholders was ¥77,207,320.73, reflecting a 9.55% year-on-year growth [4] Future Plans - The company is considering various forms of incentive management for its management and key employees, although no stock incentive plans are currently in place [4] - The company will continue to enhance its marketing and sales efforts, including talent development and promotion of sales personnel [3]